Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer

Table 2 Multivariate survival analyses for distant metastasis-free survival and overall survival

	DMFS			OS
	p value	HR	95% CI	p value	HR	95% CI
Age (≥ 60 vs. < 60 years)	0.017	0.99	0.98–1.00	< 0.001	1.02	1.03–1.06
Sex (male vs. female)	0.606	1.07	0.84–1.36	0.896	0.90	0.60–1.33
Clinical T stage (icT3/4 vs. icT1/2)	0.529	1.20	0.68–2.11	0.479	1.28	0.53–3.08
Clinical N stage (icN1/2 vs. icN0)	0.961	0.93	0.70–1.391	0.160	0.73	0.46–1.14
RT modality (tomotherapy vs. 3D-CRT)	0.459	1.12	0.83–1.53	0.354	0.73	0.38–1.41
Year of diagnosis (> 2013 vs. ≤ 2013)	0.852	0.97	0.72–1.31	< 0.001	0.51	0.51–0.52
PostRT NLR ≥ 4.0 vs. < 4.0	0.004	1.42	1.12–1.80	< 0.001	2.22	1.54–3.20
ypT (ypT3/4 vs. ypT1/2)	< 0.001	1.96	1.46–2.62	0.001	2.13	1.34–3.37
ypN (ypN1/2 vs. ypN0)	< 0.001	2.43	1.80–3.27	0.167	1.37	0.88–2.15
Adjuvant chemotherapy (no vs. yes)	0.552	0.91	0.67–1.24	0.700	0.92	0.60–1.41
RT fractionation (LCRT vs. SCRT)	0.417	0.44	0.06–3.17	0.962	< 0.01	0.00–4.34E+181

DMFS distant metastasis-free survival, OS overall survival, HR hazard ratio, CI confidence interval, NLR neutrophil-to-lymphocyte ratio, LCRT long-course RT, SCRT short-course RT

ISSN: 1748-717X